Business Description
Integra Lifesciences Holdings Corp
NAICS : 339112
SIC : 3841
ISIN : US4579852082
Share Class Description:
STU:IL3: Ordinary SharesTotal Employee Number:
4,427Description
Integra Lifesciences Holdings Corp is a New Jersey-based medical equipment company focused on developing products for regenerative therapy, extremity orthopedics, and neurosurgical applications. The firm is organized into two primary segments: Codman specialty surgical and Tissue technologies. Codman Specialty Surgical generates maximum revenue from its segmental operations. Integra serves Europe, Asia Pacific, and the rest of the world whilst it derives key revenue from domestic sales. The company operates in United States, Europe, Asia Pacific, and Rest of the World.
Financial Strength
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 0.13 | |||||
Equity-to-Asset | 0.29 | |||||
Debt-to-Equity | 1.96 | |||||
Debt-to-EBITDA | 8.36 | |||||
Interest Coverage | 0.71 | |||||
Piotroski F-Score | 5/9 | |||||
Altman Z-Score | 1.32 | |||||
Beneish M-Score | -2.69 | |||||
WACC vs ROIC | ||||||
Growth Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 4.6 | |||||
3-Year EPS without NRI Growth Rate | -12.8 | |||||
3-Year Book Growth Rate | -14.7 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 8.25 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 3 |
Momentum Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 49.31 | |||||
9-Day RSI | 43.44 | |||||
14-Day RSI | 43.7 | |||||
3-1 Month Momentum % | 21.83 | |||||
6-1 Month Momentum % | 80.21 | |||||
12-1 Month Momentum % | 36.22 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 3.6 | |||||
Quick Ratio | 2.11 | |||||
Cash Ratio | 0.83 | |||||
Days Inventory | 226.9 | |||||
Days Sales Outstanding | 60.13 | |||||
Days Payable | 42.08 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | 2.4 | |||||
Shareholder Yield % | -2.3 |
Profitability Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 52.47 | |||||
Operating Margin % | 3.98 | |||||
Net Margin % | -0.44 | |||||
EBITDA Margin % | 14.88 | |||||
FCF Margin % | 0.7 | |||||
OCF Margin % | 5.17 | |||||
ROE % | -0.7 | |||||
ROA % | -0.2 | |||||
ROIC % | 2.09 | |||||
3-Year ROIIC % | 129.88 | |||||
ROC (Joel Greenblatt) % | 7.79 | |||||
ROCE % | 2.93 | |||||
Years of Profitability over Past 10-Year | 8 | |||||
Moat Score | 6 | |||||
Tariff Resilience Score | 7 |
GF Value Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Forward PE Ratio | 6.65 | |||||
PE Ratio without NRI | 6.84 | |||||
Shiller PE Ratio | 38.47 | |||||
Price-to-Owner-Earnings | 78.93 | |||||
PS Ratio | 0.79 | |||||
PB Ratio | 1.26 | |||||
Price-to-Free-Cash-Flow | 114.12 | |||||
Price-to-Operating-Cash-Flow | 15.27 | |||||
EV-to-EBIT | 33.69 | |||||
EV-to-Forward-EBIT | 13.1 | |||||
EV-to-EBITDA | 12.6 | |||||
EV-to-Forward-EBITDA | 12.02 | |||||
EV-to-Revenue | 1.87 | |||||
EV-to-Forward-Revenue | 1.56 | |||||
EV-to-FCF | 266.24 | |||||
Price-to-GF-Value | 0.8 | |||||
Price-to-Projected-FCF | 0.71 | |||||
Price-to-Median-PS-Value | 0.26 | |||||
Earnings Yield (Greenblatt) % | 2.97 | |||||
FCF Yield % | 0.88 | |||||
Forward Rate of Return (Yacktman) % | 5.18 |
Integra Lifesciences Holdings Corp Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Integra Lifesciences Holdings Corp Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| Fourth quarter earnings conference call for 2026 | 2027-02-26 08:30 | In 180 days | ||
| Annual report for 2026 | 2027-02-26 | In 179 days | ||
| Fourth quarter earnings results for 2026 | 2027-02-26 | In 179 days | ||
| Third quarter earnings conference call for 2026 | 2026-10-30 08:30 | In 61 days | ||
| Third quarter earnings results for 2026 | 2026-10-30 | In 60 days | ||
| Second quarter earnings conference call for 2026 | 2026-07-29 08:30 | 17.30 (+1.76%) | ||
| Second quarter earnings results for 2026 | 2026-07-29 | 17.30 (+1.76%) | ||
| Truist Securities MedTech Conference | 2026-06-16 15:00 | 14.90 (-2.61%) | ||
| Guidance call for 2026 | 2026-06-03 10:30 | 13.50 (+1.50%) | ||
| Guidance call for 2026 | 2026-05-12 16:20 | 12.00 (+2.56%) |
Show
Entries
Press Release
Articles on Integra Lifesciences Holdings Corp
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers